<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00434668</url>
  </required_header>
  <id_info>
    <org_study_id>TOGA 0501</org_study_id>
    <secondary_id>Eudra CT 2005-004029-24</secondary_id>
    <nct_id>NCT00434668</nct_id>
  </id_info>
  <brief_title>Evaluation of Tolerability of Adjuvant Cisplatin/Docetaxel in Completely Resected Stage IB/II Non-Small Cell Lung Cancer</brief_title>
  <acronym>TOLEDO</acronym>
  <official_title>Randomized Phase II Study Evaluating The Tolerability Of Adjuvant Docetaxel-based Chemotherapy For Completely Resected Stage IB-II Non-Small Cell Lung Cancer (NSCLC): Toledo Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Antwerp</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universiteit Antwerpen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Antwerp</source>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the tolerability (in terms of drug delivery and
      toxicity) of four cycles of adjuvant docetaxel plus cisplatin in patients with completely
      resected stage IB-II Non-Small Cell Lung Cancer. To avoid a selection bias, eligible patients
      will be randomised to receive cisplatin/docetaxel or cisplatin/vinorelbine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Success of delivery treatment; data collected during chemotherapy treatment</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity (occurrence of any grade 4 toxicity); data collected at the end of each cycle</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall toxicity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival and overall survival</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">99</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin/docetaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin/vinorelbine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  completely resected pathological stage IB or II NSCLC

          -  adequate haematological, renal and liver function and condition

        Exclusion Criteria:

          -  previous chemo or radiotherapy for NSCLC

          -  bronchoalveolar cell subtype

          -  second active primary malignancy or serious concomitant medical disease

          -  difficulties with adequate follow-up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul R. Germonpre, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universiteit Antwerpen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ZNA Middelheim</name>
      <address>
        <city>Antwerpen</city>
        <state>Antwerp</state>
        <zip>2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Antwerp</name>
      <address>
        <city>Edegem</city>
        <state>Antwerp</state>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Augustinus ziekenhuis</name>
      <address>
        <city>Wilrijk</city>
        <state>Antwerp</state>
        <zip>2610</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2007</study_first_submitted>
  <study_first_submitted_qc>February 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2007</study_first_posted>
  <last_update_submitted>November 29, 2010</last_update_submitted>
  <last_update_submitted_qc>November 29, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 30, 2010</last_update_posted>
  <responsible_party>
    <name_title>Prof Dr P Germonpr√©</name_title>
    <organization>Thoracale Oncologie Groep Antwerpen</organization>
  </responsible_party>
  <keyword>Non-Small Cell Lung Cancer</keyword>
  <keyword>NSCLC</keyword>
  <keyword>Adjuvant chemotherapy for completely resected NSCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

